ethyl 3-chlorosulfonyl-1-methylpyrazole-4-carboxylate

We are ethyl 3-chlorosulfonyl-1-methylpyrazole-4-carboxylate CAS:93621-38-6 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

CAS No: 93621-38-6
Product Name: ethyl 3-chlorosulfonyl-1-methylpyrazole-4-carboxylate
Other Name:
ethyl 3-chlorosulfonyl-1-methylpyrazole-4-carboxylate
 
Molecular Formula: C7H9ClN2O4S
Molecular Weight: 252.67500
Exact Mass: 251.99700
PSA: 86.64000
LogP: 1.60510
 
Specification
Appearance: White solid
Assay: ≥99.0%
Loss on drying: ≤0.5%
 
Application
Intermediates of Pyrazosulfuron-Ethyl CAS: 93697-74-6.
Be used as pesticide intermediate, mainly used in the synthesis of the herbicide Pyrazosulfuron-Ethyl.
 
Package: 25kg/drum, can also be designed according to customer requirements.
Storage: Store in cool place. Keep container tightly closed in a dry and well-ventilated place.

ethyl 3-chlorosulfonyl-1-methylpyrazole-4-carboxylate


Related News: With the improvement of domestic GMP management level, the increase of process development capabilities and international certification experience, China has already possessed the conditions for developing characteristic APIs.24666-56-6 “Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management,” Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.2- 甲基 -3- 甲硫 基 呋喃 CAS:63012-97-5 “Our collaboration with Mankind demonstrates our commitment towards providing novel, innovative treatment options for efficient diabetes management,” Glenmark Pharmaceuticals President, India Formulations, Middle East and Africa Sujesh Vasudevan said.1-Methyl-3-phenoxybenzene CAS:3586-14-9 Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).Rigosertib is a small molecule that inhibits cellular signaling in cancer cells by acting as a RAS mimetic. Current clinical development of rigosertib is centered upon the therapeutic management of MDS, a heterogeneous group of bone marrow disorders characterized by ineffective hematopoiesis that often develop into acute myeloid leukaemia (AML).

Related Products
Product Name
2-methyl-2-oxazoline View Details
1-Bromo-2,5-difluorobenzene View Details
2,3-Dichlorobenzotrifluoride View Details
4,4′-Dimethoxytrityl chloride manufacturer 3-Bromophthalide manufacturer 1-hexadecyl-3-methylimidazolium chloride manufacturer 2-Chloro-1,3-dimethylbenzene manufacturer beta-D-Ribofuranose 1,2,3,5-tetraacetate manufacturer